Optimizing Drug Dosing for the Treatment of Chronic Lvmohocvtic Leukemia

摘要

The treatment paradigm for chronic lymphocytic leukemia (CLL) has changed substantially in the past several years. There are now targeted therapies, such as the Brutons tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica, Pharmacyclics/Janssen), the phosphoinosi-tide 3 (PI3) kinase inhibitors idelalisib (Zydelig, Gilead) and duvelisib (Copiktra, Verastem), and the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (Venclexta, AbbVie/Genentech). All of these therapies are approved by the US Food and Drug Administration for patients with CLL. They are administered orally. In randomized clinical trials, these therapies were shown to be superior to the standard regimens. Many other new drugs are also in development for patients with CLL.